ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Adam Christian Vilmar; E Santoni-Rugiu; J B Sørensen

doi:10.1093/annonc/mdq053

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Adam Christian Vilmar, E Santoni-Rugiu, J B Sørensen

Afdeling for Patologi

70 Citationer (Scopus)

Abstract

Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.

Originalsprog	Engelsk
Tidsskrift	Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Vol/bind	21
Udgave nummer	9
Sider (fra-til)	1817-24
Antal sider	8
DOI	https://doi.org/10.1093/annonc/mdq053
Status	Udgivet - 1 sep. 2010

Adgang til dokumentet

10.1093/annonc/mdq053

Citationsformater

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial. / Vilmar, Adam Christian; Santoni-Rugiu, E; Sørensen, J B.
I: Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, Bind 21, Nr. 9, 01.09.2010, s. 1817-24.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

@article{b3596bcfda744fbdaf314f424af0e3ef,

title = "ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial",

abstract = "Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.",

author = "Vilmar, {Adam Christian} and E Santoni-Rugiu and S{\o}rensen, {J B}",

year = "2010",

month = sep,

day = "1",

doi = "10.1093/annonc/mdq053",

language = "English",

volume = "21",

pages = "1817--24",

journal = "Annals of oncology : official journal of the European Society for Medical Oncology / ESMO",

issn = "1569-8041",

publisher = "Oxford University Press",

number = "9",

}

TY - JOUR

T1 - ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

AU - Vilmar, Adam Christian

AU - Santoni-Rugiu, E

AU - Sørensen, J B

PY - 2010/9/1

Y1 - 2010/9/1

N2 - Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.

AB - Customized chemotherapy is likely to improve outcome in patients with advanced non-small-cell lung cancer (NSCLC). Excision repair cross-complementation group 1 (ERCC1) is a promising biomarker; however, current evidence is inadequate. Impact of ERCC1 status was evaluated among patients participating in a large randomized chemotherapy trial.

U2 - 10.1093/annonc/mdq053

DO - 10.1093/annonc/mdq053

M3 - Journal article

C2 - 20332140

SN - 1569-8041

VL - 21

SP - 1817

EP - 1824

JO - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

JF - Annals of oncology : official journal of the European Society for Medical Oncology / ESMO

IS - 9

ER -

ERCC1 and histopathology in advanced NSCLC patients randomized in a large multicenter phase III trial

Abstract

Adgang til dokumentet

Fingeraftryk

Citationsformater